https://www.pharmaradar360.com/article/ai-drug-discovery-on-the-eve-of-full-value-realization-in-modern-pharmaceutical-06757b6282d027abPharmaRadar360en2026-09-26T10:52:25.000ZAI Drug Discovery: On the Eve of Full Value Realization in Modern Pharmaceutical Innovationhttps://www.pharmaradar360.com/article/clinical-data-harmonization-is-the-bottleneck-for-life-sciences-ai-6523456644754b15PharmaRadar360en2026-09-26T10:37:04.000ZClinical data harmonization is the bottleneck for life sciences AIhttps://www.pharmaradar360.com/article/commentary-the-prescription-drug-affordability-board-is-working-it-s-time-to-pre-c716bb20e31d28e8PharmaRadar360en2026-09-26T10:18:42.000ZCommentary: The Prescription Drug Affordability Board is working, it's time to press forward, not backhttps://www.pharmaradar360.com/article/results-are-due-monday-from-a-study-of-two-potential-treatments-for-an-age-relat-87cd3e491349b862PharmaRadar360en2026-09-26T10:05:31.000ZResults are due Monday from a study of two potential treatments for an age-related eye disease.https://www.pharmaradar360.com/article/the-drug-industry-s-care-gap-novo-aims-to-diversify-and-more-94fb54d839beca63PharmaRadar360en2026-09-26T10:00:00.000ZThe drug industry’s care gap; Novo aims to diversify; and morehttps://www.pharmaradar360.com/article/russia-hits-kyiv-pharmaceutical-plant-second-time-in-a-week-f81a10d67ee2ab91PharmaRadar360en2026-09-26T09:31:06.000ZRussia Hits Kyiv Pharmaceutical Plant Second Time in a Weekhttps://www.pharmaradar360.com/article/russian-forces-strike-darnytsia-pharmaceutical-plant-in-kyiv-again-14945dbed4fb36a5PharmaRadar360en2026-09-26T08:58:00.000ZRussian forces strike Darnytsia pharmaceutical plant in Kyiv againhttps://www.pharmaradar360.com/article/ultragenyx-pharmaceutical-inc-nasdaq-rare-stock-has-consensus-price-target-of-34-cc9516ac59c30051PharmaRadar360en2026-09-26T08:34:28.000ZUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Stock Has Consensus Price Target of $34.58 According to Analystshttps://www.pharmaradar360.com/article/eli-002-7p-phase-2-data-selected-for-esmo-2026-oral-presentation-51bca2865302a680PharmaRadar360en2026-09-26T06:43:43.000ZELI-002 7P Phase 2 Data Selected for ESMO 2026 Oral Presentationhttps://www.pharmaradar360.com/article/russia-struck-the-pharmaceutical-company-darnitsa-for-the-second-time-in-four-da-e1a4757d3eb9349fPharmaRadar360en2026-09-26T06:32:53.000ZRussia struck the pharmaceutical company "Darnitsa" for the second time in four dayshttps://www.pharmaradar360.com/article/total-assets-of-indrayani-biotech-ltd-right-2026-25-06-26-for-shares-bse-indra-r-0ebd88a86d57b92bPharmaRadar360en2026-09-26T05:34:13.000ZTotal assets of Indrayani Biotech Ltd. Right 2026-25.06.26 For Shares – BSE:INDRA_REhttps://www.pharmaradar360.com/article/greenland-mines-nasdaq-grml-sets-q4-biotech-spin-off-as-company-sharpens-critica-827b8cea89bf7fccPharmaRadar360en2026-09-26T03:52:02.000ZGreenland Mines (NASDAQ: GRML) Sets Q4 Biotech Spin-Off as Company Sharpens Critical Minerals Focushttps://www.pharmaradar360.com/article/total-liabilities-of-indrayani-biotech-ltd-right-2026-25-06-26-for-shares-bse-in-2ba17615a74ef7daPharmaRadar360en2026-09-26T03:12:20.000ZTotal liabilities of Indrayani Biotech Ltd. Right 2026-25.06.26 For Shares – BSE:INDRA_REhttps://www.pharmaradar360.com/article/acadia-pharmaceuticals-announces-phase-3-enabling-topline-results-from-phase-2-r-bfc2d18115b8e3c4PharmaRadar360en2026-09-26T02:45:00.000ZAcadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP)https://www.pharmaradar360.com/article/burning-rock-biotech-ltd-bnr-shares-surge-3-3-what-gf-scor-5e0b4dd39ed88219PharmaRadar360en2026-09-26T02:35:46.000ZBurning Rock Biotech Ltd (BNR) Shares Surge 3.3% -- What GF Scorhttps://www.pharmaradar360.com/article/maia-biotechnology-files-resale-prospectus-for-751-879-shares-994c1b7db293f72aPharmaRadar360en2026-09-26T02:30:37.000ZMAIA Biotechnology files resale prospectus for 751,879 shareshttps://www.pharmaradar360.com/article/eli-lilly-makes-another-biotech-bet-ahead-of-retatrutide-data-lly-stock-surges-t-f277b743c44c8524PharmaRadar360en2026-09-26T01:53:15.000ZEli Lilly Makes Another Biotech Bet Ahead Of Retatrutide Data – LLY Stock Surges To Highest In Over 2 Monthshttps://www.pharmaradar360.com/article/ai-natural-medicine-biotech-enveda-raises-311m-series-e-9ab31ef431554506PharmaRadar360en2026-09-26T01:50:01.000ZAI Natural-Medicine Biotech Enveda Raises $311M Series Ehttps://www.pharmaradar360.com/article/ag-fitch-urges-nsc-to-protect-glp-1-drugs-cda4d5edfcdcd63cPharmaRadar360en2026-09-26T01:05:16.000ZAG Fitch urges NSC to protect GLP-1 Drugshttps://www.pharmaradar360.com/article/how-chinese-biotech-is-graduating-from-licensing-deals-to-broader-partnerships-183cd687d9726f33PharmaRadar360en2026-09-26T01:00:08.000ZHow Chinese biotech is graduating from licensing deals to broader partnershipshttps://www.pharmaradar360.com/article/new-biotech-startup-at-stanford-is-run-by-thousands-of-ai-agents-475453ac2c308eefPharmaRadar360en2026-09-26T00:43:04.000ZNew biotech startup at Stanford is run by thousands of AI agentshttps://www.pharmaradar360.com/article/food-biotech-is-moving-behind-the-label-0f6be4fba0036f13PharmaRadar360en2026-09-26T00:41:07.000ZFood Biotech Is Moving Behind the Labelhttps://www.pharmaradar360.com/article/total-debt-of-indrayani-biotech-ltd-right-2026-25-06-26-for-shares-bse-indra-re-4e3da3a19b763c2aPharmaRadar360en2026-09-26T00:21:58.000ZTotal debt of Indrayani Biotech Ltd. Right 2026-25.06.26 For Shares – BSE:INDRA_REhttps://www.pharmaradar360.com/article/chugai-pharmaceutical-and-2-japanese-ai-healthcare-stocks-to-own-dad20d1ebc13d0efPharmaRadar360en2026-09-26T00:13:00.000ZChugai Pharmaceutical And 2 Japanese AI Healthcare Stocks To Ownhttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-6d6db8d53ff59d8cPharmaRadar360en2026-09-26T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9794-4-crore-consolidated-revenue-and-e2-82-b9206-5-crore-o-5f007ead935d5468PharmaRadar360en2026-09-26T00:00:00.000Znatco records %e2%82%b9794 4 crore consolidated revenue and %e2%82%b9206 5 crore of profit after tax for q1 fy27https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-33e8b6b6ad98b572PharmaRadar360en2026-09-26T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-olaparib-tablets-from-the-united-states-fo-d811b52390b0afd8PharmaRadar360en2026-09-26T00:00:00.000Znatco receives tentative approval for olaparib tablets from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-7c46eedf80fd409fPharmaRadar360en2026-09-26T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-72b59d7174a3b9a3PharmaRadar360en2026-09-26T00:00:00.000Znatco pharma limited gets approval from its board of directors for increasing its stake in adcock ingram holdings proprietary limited to 49https://www.pharmaradar360.com/article/natco-pharma-limited-completes-acquisition-of-additional-13-25-stake-in-adcock-i-14e9196c217b943dPharmaRadar360en2026-09-26T00:00:00.000Znatco pharma limited completes acquisition of additional 13 25 stake in adcock ingram holdings proprietary limitedhttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-3fd550483f66794aPharmaRadar360en2026-09-26T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-limited-announces-conclusion-of-us-fda-inspection-at-visakhapatnam-563c93e91fa18339PharmaRadar360en2026-09-26T00:00:00.000Znatco pharma limited announces conclusion of us fda inspection at visakhapatnam andhra pradesh finished dosage formulations fdf unithttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-d0e1b50f11e06745PharmaRadar360en2026-09-26T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-2089d34b685056ebPharmaRadar360en2026-09-26T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-c77eeaad812063d0PharmaRadar360en2026-09-26T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/investment-of-us-14-million-in-egenesis-inc-by-natco-pharma-canada-inc-and-natco-a5efdea1fa732b7ePharmaRadar360en2026-09-26T00:00:00.000Zinvestment of us 14 million in egenesis inc by natco pharma canada inc and natco pharma south africa proprietary limitedhttps://www.pharmaradar360.com/article/home-page-e05c95cbe49665bePharmaRadar360en2026-09-26T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/evaluating-the-clinical-use-of-cefoperazone-sulbactam-and-post-discharge-antibio-de43bf2af77c554dPharmaRadar360en2026-09-26T00:00:00.000ZEvaluating the Clinical Use of Cefoperazone/ Sulbactam and Post-discharge Antibiotics Practices in Infectious Diseases Patientshttps://www.pharmaradar360.com/article/polycystic-ovary-syndrome-pcos-associated-infertility-clinical-insights-and-emer-83c6bc6c8507db43PharmaRadar360en2026-09-26T00:00:00.000ZPolycystic Ovary Syndrome (PCOS) -Associated Infertility: Clinical Insights and Emerging Deep Learning Approaches for Early Detection and Predictionhttps://www.pharmaradar360.com/article/low-dose-silodosin-for-premature-ejaculation-a-clinical-evaluation-45c0c2795e660c9fPharmaRadar360en2026-09-26T00:00:00.000ZLow-Dose Silodosin for Premature Ejaculation: A Clinical Evaluationhttps://www.pharmaradar360.com/article/sociodemographic-and-clinical-characteristics-of-tuberculosispositivity-and-rifa-4ce74de0c5bbbec3PharmaRadar360en2026-09-26T00:00:00.000ZSociodemographic and Clinical Characteristics of TuberculosisPositivity and Rifampicin Resistance among Presumptive Patients inSouthern Punjab, Pakistan: A Cross-Sectional Studyhttps://www.pharmaradar360.com/article/african-hla-diversity-and-its-implications-for-transfusion-transplantation-infec-97b857cf9a314545PharmaRadar360en2026-09-26T00:00:00.000ZAfrican HLA Diversity and Its Implications for Transfusion, Transplantation, Infectious-Disease Immunity, Vaccination and Pharmacogenomicshttps://www.pharmaradar360.com/article/harnessing-coordinated-cd4-and-cd8-t-cell-immunity-for-virus-specific-adoptive-i-1b602c6ec922594cPharmaRadar360en2026-09-26T00:00:00.000ZHarnessing Coordinated CD4⁺ and CD8⁺ T-Cell Immunity for Virus-Specific Adoptive Immunotherapy in Africahttps://www.pharmaradar360.com/article/induced-pluripotent-stem-cell-derived-chimeric-antigen-receptor-natural-killer-c-d1be5f82d021a8a7PharmaRadar360en2026-09-26T00:00:00.000ZInduced pluripotent stem cell-derived chimeric antigen receptor natural killer cells: Engineering innovations, translational hurdles and clinical prospects in immune therapyhttps://www.pharmaradar360.com/article/efficacy-and-safety-of-oral-paracetamol-versus-intravenous-paracetamol-in-preter-1aeadb35921e3545PharmaRadar360en2026-09-26T00:00:00.000ZEfficacy and safety of oral paracetamol versus intravenous paracetamol in preterm infants with patent ductus arteriosus: a randomised controlled trialhttps://www.pharmaradar360.com/article/p4ha3-promotes-gastric-cancer-cell-proliferation-and-invasion-via-the-pi3k-akt-m-33a6b1c82ca3a9d0PharmaRadar360en2026-09-26T00:00:00.000ZP4HA3 promotes gastric cancer cell proliferation and invasion via the PI3K/AKT/mTOR signaling pathway and regulates glycolytic metabolic reprogramminghttps://www.pharmaradar360.com/article/comparative-evaluation-of-medication-adherence-and-health-related-quality-of-lif-ee8db90c935c5ed5PharmaRadar360en2026-09-26T00:00:00.000ZComparative Evaluation of Medication Adherence and Health-Related Quality of Life with SGLT-2 Versus DPP-4 Inhibitors in Type 2 Diabetes Mellitus: A 12-Month Prospective Observational Studyhttps://www.pharmaradar360.com/article/terapia-hormonal-de-la-menopausia-reevaluacion-del-balance-riesgo-beneficio-dos-dd70098654c62292PharmaRadar360en2026-09-26T00:00:00.000ZTERAPIA HORMONAL DE LA MENOPAUSIA: REEVALUACIÓN DEL BALANCE RIESGO-BENEFICIO DOS DÉCADAS DESPUÉS DEL ESTUDIO WOMEN'S HEALTH INITIATIVE (WHI)https://www.pharmaradar360.com/article/digital-twin-of-drug-induced-liver-injury-and-systemic-adverse-drug-reactions-in-0551ae2a8f18f7f0PharmaRadar360en2026-09-26T00:00:00.000ZDIGITAL TWIN OF DRUG-INDUCED LIVER INJURY AND SYSTEMIC ADVERSE DRUG REACTIONS IN MASS MEDICATION SCENARIOS: PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELShttps://www.pharmaradar360.com/article/the-intersection-of-artificial-intelligence-and-intellectual-property-the-impact-66b51a1456a6de5bPharmaRadar360en2026-09-26T00:00:00.000ZThe Intersection of Artificial Intelligence and Intellectual Property: The Impact of Data Exclusivity Policies on Pharmaceutical Production in Africahttps://www.pharmaradar360.com/article/iron-accumulation-in-non-transfusion-dependent-thalassemia-from-molecular-mechan-d1c333f0838c0072PharmaRadar360en2026-09-26T00:00:00.000ZIron accumulation in non-transfusion-dependent thalassemia: From molecular mechanisms to clinical practicehttps://www.pharmaradar360.com/article/effects-of-sauna-and-waon-therapy-on-cardiovascular-function-and-clinical-outcom-2d7175966a24da73PharmaRadar360en2026-09-26T00:00:00.000ZEffects of Sauna and Waon Therapy on Cardiovascular Function and Clinical Outcomes in Patients with Chronic Heart Failure or Coronary Artery Disease: Systematic Reviewhttps://www.pharmaradar360.com/article/a-case-of-atypical-occult-hepatitis-b-infection-obi-with-hbsag-negativity-and-hi-d4a1743a51e55130PharmaRadar360en2026-09-26T00:00:00.000ZA case of Atypical Occult Hepatitis B Infection (OBI) with HBsAg Negativity and High Anti-HBs Titer: Clinical implicationshttps://www.pharmaradar360.com/article/effect-of-multi-modal-training-in-patients-with-mild-cognitive-impairment-a-rand-423debf0992ec711PharmaRadar360en2026-09-26T00:00:00.000ZEffect of Multi-Modal Training in Patients With Mild Cognitive Impairment: A Randomized Controlled Pilot Trialhttps://www.pharmaradar360.com/article/sex-differences-in-sentiment-scored-vocabulary-patterns-in-vaers-free-text-narra-3d06f6c8aa9c3a7bPharmaRadar360en2026-09-26T00:00:00.000ZSex Differences in Sentiment-Scored Vocabulary Patterns in VAERS Free-Text Narratives of Four Major Vaccine Categorieshttps://www.pharmaradar360.com/article/enhancing-skin-penetration-of-a-hydrophilic-large-molecular-weight-compound-usin-f56a6a4d8e2bb9a3PharmaRadar360en2026-09-26T00:00:00.000ZEnhancing Skin Penetration of a Hydrophilic, Large Molecular Weight Compound Using a Nanoparticle-in-Oil Dispersionhttps://www.pharmaradar360.com/article/comparison-of-salivary-cortisol-cortisone-and-dexamethasone-with-serum-measureme-d76f10631ca18dd3PharmaRadar360en2026-09-26T00:00:00.000ZComparison of Salivary Cortisol, Cortisone, and Dexamethasone with Serum Measurements Across Dynamic Adrenal Testinghttps://www.pharmaradar360.com/article/fluid-intolerance-signals-as-bedside-safety-limits-during-early-septic-shock-res-f4a9bdb767151ed4PharmaRadar360en2026-09-26T00:00:00.000ZFluid-intolerance signals as bedside safety limits during early septic shock resuscitation: a multicenter randomized trialhttps://www.pharmaradar360.com/article/when-the-system-fails-the-community-leads-field-insights-from-the-self-efficacy-93ebbf8aed800074PharmaRadar360en2026-09-26T00:00:00.000ZWhen the system fails, the community leads: field insights from the self-efficacy and knowledge (SEEK) trial during Lebanon’s 2024 active conflicthttps://www.pharmaradar360.com/article/clinical-biochemical-and-genetic-spectra-of-carnosinemia-a-systematic-review-of-e2c70be37f41686ePharmaRadar360en2026-09-26T00:00:00.000ZClinical, biochemical and genetic spectra of carnosinemia: a systematic review of case reports and case serieshttps://www.pharmaradar360.com/article/postprandial-lipopolysaccharide-after-a-saturated-compared-to-monounsaturated-fa-d14b5d2d6417c0fbPharmaRadar360en2026-09-26T00:00:00.000ZPostprandial lipopolysaccharide after a saturated compared to monounsaturated fatty acid enriched high fat meal in older adults: a randomized control trialhttps://www.pharmaradar360.com/article/when-nudges-are-not-enough-an-ethics-of-escalating-behavioural-interventions-in-93e891b830e4c076PharmaRadar360en2026-09-26T00:00:00.000ZWhen nudges are not enough: an ethics of escalating behavioural interventions in clinical decision-makinghttps://www.pharmaradar360.com/article/perceptions-of-micro-learning-modules-on-knowledge-retention-and-clinical-decisi-0a8cffb9f2848e80PharmaRadar360en2026-09-26T00:00:00.000ZPerceptions of micro-learning modules on knowledge retention and clinical decision-making among physiotherapists: a cross-sectional studyhttps://www.pharmaradar360.com/article/platinum-based-chemotherapy-and-nephrotoxicity-frequency-clinical-characteristic-d4cca52e1258bb58PharmaRadar360en2026-09-26T00:00:00.000ZPlatinum-based chemotherapy and nephrotoxicity: frequency, clinical characteristics and outcomes in a mexican tertiary-centre cohorthttps://www.pharmaradar360.com/article/machine-learning-models-combining-multimodal-ultrasound-and-clinical-factors-for-0587d6eee90880e1PharmaRadar360en2026-09-26T00:00:00.000ZMachine learning models combining multimodal ultrasound and clinical factors for predicting ischemic stroke risk in patients with carotid plaqueshttps://www.pharmaradar360.com/article/idiopathic-granulomatous-inflammation-of-the-periocular-structures-in-four-dogs-8d673f367bc771fePharmaRadar360en2026-09-26T00:00:00.000ZIdiopathic Granulomatous Inflammation of the Periocular Structures in Four Dogs: Clinical, Histopathological, and Imaging Findings and Therapeutic Outcomehttps://www.pharmaradar360.com/article/preparation-and-i-in-vitro-i-evaluation-of-amphotericin-b-chondroitin-sulfate-po-67ac2740a793f501PharmaRadar360en2026-09-26T00:00:00.000ZPreparation and <i>in vitro</i> evaluation of amphotericin B-chondroitin sulfate polymer prodrughttps://www.pharmaradar360.com/article/effects-of-virtual-reality-based-aerobic-exercise-versus-traditional-aerobic-exe-0726fa7784af4fbdPharmaRadar360en2026-09-26T00:00:00.000ZEffects of virtual reality-based aerobic exercise versus traditional aerobic exercise training on physical fitness, functional capacity, and quality of life in individuals with Down syndrome: DOWNFIT (Down Syndrome Fitness Intervention Trial) randomized controlled trialhttps://www.pharmaradar360.com/article/clinician-curated-chatgpt-4o-and-deepseek-r1-assisted-exercise-programmes-added-1854cdd7da17f8a5PharmaRadar360en2026-09-26T00:00:00.000ZClinician-curated ChatGPT-4o– and DeepSeek-R1–assisted exercise programmes added to standard physiotherapy for subacromial pain syndrome: a triple-masked randomized controlled trialhttps://www.pharmaradar360.com/article/benchmarking-model-based-design-of-experiment-approaches-with-a-pharmaceutical-c-39b3209501f13f07PharmaRadar360en2026-09-26T00:00:00.000ZBenchmarking model-based design of experiment approaches with a pharmaceutical crystallisation emulatorhttps://www.pharmaradar360.com/article/semaglutide-and-tirzepatide-in-cardiovascular-and-cardiometabolic-risk-managemen-3a1c317d994a2f39PharmaRadar360en2026-09-26T00:00:00.000ZSemaglutide and Tirzepatide in Cardiovascular and Cardiometabolic Risk Management: Evidence Maturity, Patient Selection, and Real-World Implementationhttps://www.pharmaradar360.com/article/relationship-between-breast-arterial-calcification-detected-on-mammography-and-c-b61df578ae71bdd2PharmaRadar360en2026-09-26T00:00:00.000ZRelationship Between Breast Arterial Calcification Detected on Mammography and Carotid Intima Media Thickness as a Marker for Subclinical Atherosclerosishttps://www.pharmaradar360.com/article/health-literacy-primary-healthcare-accessibility-and-hypertension-self-care-mana-161c74695fc7a346PharmaRadar360en2026-09-26T00:00:00.000ZHealth Literacy, Primary Healthcare Accessibility and Hypertension Self-Care Management Among Adults in an Urban Slum of New Delhi: A Community-Based Cross-Sectional Studyhttps://www.pharmaradar360.com/article/clinicians-perspectives-on-the-design-of-multi-output-ai-based-early-warning-sys-96c5ad937ea54cfdPharmaRadar360en2026-09-26T00:00:00.000ZClinicians’ Perspectives on the Design of Multi-Output AI-Based Early Warning Systems for Clinical Deterioration: A Qualitative Analysishttps://www.pharmaradar360.com/article/association-of-the-5-item-modified-frailty-index-and-chronological-age-with-post-cbf14f8eb36fce46PharmaRadar360en2026-09-26T00:00:00.000ZAssociation of the 5-item modified frailty index and chronological age with postoperative length of stay after CRS–HIPEC: a single-centre cohort studyhttps://www.pharmaradar360.com/article/internalized-weight-stigma-and-associated-clinical-features-in-treatment-seeking-83ea0ad14fda1f23PharmaRadar360en2026-09-26T00:00:00.000ZInternalized weight stigma and associated clinical features in treatment-seeking adults with obesity: a multicenter Italian studyhttps://www.pharmaradar360.com/article/automated-reporting-for-serum-immunofixation-electrophoresis-using-a-two-stage-d-43c8f7d90ebbeb81PharmaRadar360en2026-09-26T00:00:00.000ZAutomated Reporting for Serum Immunofixation Electrophoresis Using a Two-Stage Decision-Support Systemhttps://www.pharmaradar360.com/article/blockchain-based-pharmaceutical-supply-chain-a-scalable-and-transparent-model-fo-7c8d96259f0a09b5PharmaRadar360en2026-09-26T00:00:00.000ZBlockchain-based pharmaceutical supply chain: a scalable and transparent model for drug traceabilityhttps://www.pharmaradar360.com/article/development-and-clinical-translation-of-a-stepwise-simulation-based-curriculum-f-f94eb722ad3070c8PharmaRadar360en2026-09-26T00:00:00.000ZDevelopment and clinical translation of a stepwise simulation-based curriculum for robotic lung transplantationhttps://www.pharmaradar360.com/article/design-of-thermoresponsive-pnipam-coated-hollow-bimetallic-nanocomposites-for-ph-7d6337f875827942PharmaRadar360en2026-09-26T00:00:00.000ZDesign of thermoresponsive PNIPAM-coated hollow bimetallic nanocomposites for photothermal-enhanced drug delivery and chemo-photothermal therapyhttps://www.pharmaradar360.com/article/beyond-kpaq-improvement-reassessing-the-clinical-meaning-of-cilostazol-rosuvasta-6a232b0f64ce470dPharmaRadar360en2026-09-26T00:00:00.000ZBeyond KPAQ Improvement: Reassessing the Clinical Meaning of Cilostazol–Rosuvastatin Combination Therapy in Symptomatic Peripheral Artery Diseasehttps://www.pharmaradar360.com/article/splice-site-variants-in-neurology-from-molecular-mechanisms-to-clinical-interpre-47616a2bbc486454PharmaRadar360en2026-09-26T00:00:00.000ZSplice-site variants in neurology: from molecular mechanisms to clinical interpretation — a focused reviewhttps://www.pharmaradar360.com/article/dietary-inflammatory-potential-and-oral-periodontal-health-in-children-a-cross-s-c6073d301f8193afPharmaRadar360en2026-09-26T00:00:00.000ZDietary inflammatory potential and oral–periodontal health in children: a cross-sectional study based on the children’s dietary inflammatory index dietary inflammatory potential and oral-periodontal health in childrenhttps://www.pharmaradar360.com/article/effect-of-surface-treatment-protocols-and-thermocycling-on-the-optical-surface-a-c467701c4ba52a3bPharmaRadar360en2026-09-26T00:00:00.000ZEffect of surface treatment protocols and thermocycling on the optical, surface, and mechanical properties of additively manufactured resin materialshttps://www.pharmaradar360.com/article/influence-of-cold-plasma-activation-on-fluoride-uptake-and-demineralization-of-e-eb9109194738a3a2PharmaRadar360en2026-09-26T00:00:00.000ZInfluence of cold plasma activation on fluoride uptake and demineralization of enamelhttps://www.pharmaradar360.com/article/association-of-cannabis-use-disorder-with-clinical-outcomes-following-lumbar-spi-856f9a813f88bb67PharmaRadar360en2026-09-26T00:00:00.000ZAssociation of cannabis use disorder with clinical outcomes following lumbar spinal fusion: a propensity-matched cohort studyhttps://www.pharmaradar360.com/article/nanoliposomal-silymarin-as-a-multi-mechanistic-therapy-for-nafld-dose-dependent-cc068a3b9bcdbfcbPharmaRadar360en2026-09-26T00:00:00.000ZNanoliposomal silymarin as a multi-mechanistic therapy for NAFLD: dose-dependent amelioration of hepatic steatosis, fibrosis, and oxidative stress in a rat modelhttps://www.pharmaradar360.com/article/low-handgrip-strength-in-advanced-cancer-associated-factors-and-clinical-implica-7269a0855ff7e4c1PharmaRadar360en2026-09-26T00:00:00.000ZLow handgrip strength in advanced cancer: associated factors and clinical implications in palliative carehttps://www.pharmaradar360.com/article/novel-semi-automated-system-for-multi-dimensional-analysis-of-macular-neovascula-7bebf046e75cd0e0PharmaRadar360en2026-09-26T00:00:00.000ZNovel semi-automated system for multi-dimensional analysis of macular neovascularization: quantitative biomarkers and rule-based morphological categorization across OCTA platformshttps://www.pharmaradar360.com/article/impact-of-covid-19-on-refractive-amblyopia-risk-factors-in-5-years-old-children-b5d42cfabe22f6ffPharmaRadar360en2026-09-26T00:00:00.000ZImpact of COVID-19 on refractive amblyopia risk factors in 5-years-old children: A nationwide cross sectional studyhttps://www.pharmaradar360.com/article/the-spiz-study-rationale-and-protocol-of-a-randomized-controlled-trial-to-optimi-ba23ab4a9346904bPharmaRadar360en2026-09-26T00:00:00.000ZThe SPIZ study: rationale and protocol of a randomized controlled trial to optimize interdisciplinary care of patients following cellular therapy through a digitally supported, cross-regional and cross-sectoral care modelhttps://www.pharmaradar360.com/article/clinical-and-laboratory-characteristics-distinguishing-node-first-kawasaki-disea-4e3f1b106d63d0ffPharmaRadar360en2026-09-26T00:00:00.000ZClinical and Laboratory Characteristics Distinguishing Node-First Kawasaki Disease from Bacterial Cervical Lymphadenitis: A Systematic Reviewhttps://www.pharmaradar360.com/article/pharmaceutical-innovation-in-advanced-nanomedicine-for-the-treatment-of-hypervir-18f8abae5a555e61PharmaRadar360en2026-09-26T00:00:00.000ZPharmaceutical innovation in advanced nanomedicine for the treatment of hypervirulent and multidrug-resistant Klebsiella pneumoniae infectionshttps://www.pharmaradar360.com/article/child-human-in-the-loop-ood-detection-for-safe-clinical-deployment-63f5fa2dc79454b0PharmaRadar360en2026-09-26T00:00:00.000ZCHILD: Human-in-the-Loop OOD Detection for Safe Clinical Deploymenthttps://www.pharmaradar360.com/article/biogait-vlm-a-tri-modal-vision-language-biomechanics-framework-for-interpretable-1233b179f74e6545PharmaRadar360en2026-09-26T00:00:00.000ZBioGait-VLM: A Tri-Modal Vision–Language–Biomechanics Framework for Interpretable Clinical Gait Assessmenthttps://www.pharmaradar360.com/article/atomimed-hierarchical-atomic-fact-checking-for-universal-clinical-aware-medical-3d7e99bd2b99d254PharmaRadar360en2026-09-26T00:00:00.000ZAtomiMed: Hierarchical Atomic Fact-Checking for Universal Clinical-Aware Medical Report Evaluationhttps://www.pharmaradar360.com/article/biomass-derived-carbon-dots-based-frap-analog-for-sensitive-evaluation-of-antiox-7fc4c245e4935099PharmaRadar360en2026-09-26T00:00:00.000ZBiomass‐Derived Carbon Dots–Based FRAP Analog for Sensitive Evaluation of Antioxidant Activity: Application to Pharmaceutical Products and Plant Extractshttps://www.pharmaradar360.com/article/edsa-stock-rallied-over-50-today-what-s-ahead-for-the-small-cap-biotech-ad8c8a2cd49d9062PharmaRadar360en2026-09-25T23:26:34.000ZEDSA Stock Rallied Over 50% Today: What’s Ahead For The Small-Cap Biotech?https://www.pharmaradar360.com/article/murkowski-concerned-fda-pick-may-limit-chemical-abortion-killing-of-preborn-alas-a423c9902e1ff283PharmaRadar360en2026-09-25T23:16:57.000ZMurkowski ‘concerned’ FDA pick may limit chemical abortion killing of preborn Alaskanshttps://www.pharmaradar360.com/article/state-street-spdr-s-p-biotech-etf-xbi-stock-price-news-quote-and-history-c439df664c2384a2PharmaRadar360en2026-09-25T22:54:20.000ZState Street SPDR S&P Biotech ETF (XBI) stock price, news, quote and historyhttps://www.pharmaradar360.com/article/budd-blunt-rochester-introduce-bill-to-establish-biometrology-laboratory-program-35bcca7365f58ae5PharmaRadar360en2026-09-25T22:47:49.000ZBudd, Blunt Rochester Introduce Bill to Establish Biometrology Laboratory Program, Accelerate Development in Biotechhttps://www.pharmaradar360.com/article/zeria-pharmaceutical-co-ltd-tse-4559-looks-like-a-good-stock-and-it-s-going-ex-d-6fb6c2f2205f1cfbPharmaRadar360en2026-09-25T22:07:10.000ZZeria Pharmaceutical Co., Ltd. (TSE:4559) Looks Like A Good Stock, And It's Going Ex-Dividend Soonhttps://www.pharmaradar360.com/article/consideration-of-the-political-declaration-on-pandemic-prevention-preparedness-a-a6e8e4bc3b7ddcd2PharmaRadar360en2026-09-25T22:00:28.000ZConsideration of the Political Declaration on Pandemic Prevention, Preparedness, and Response (PPPR)https://www.pharmaradar360.com/article/fda-confirmation-hearing-gives-update-on-abortion-pill-study-under-new-leadershi-25744d59fca613e4PharmaRadar360en2026-09-25T22:00:00.000ZFDA Confirmation Hearing Gives Update on Abortion Pill Study Under New Leadershiphttps://www.pharmaradar360.com/article/community-pharmacist-prescribing-service-planned-for-october-2026-start-20a197d64ffbf786PharmaRadar360en2026-09-25T21:41:15.000ZCommunity pharmacist prescribing service planned for October 2026 starthttps://www.pharmaradar360.com/article/pharmacy-at-the-heart-of-welsh-government-s-healthcare-priorities-3e55daddcdec949fPharmaRadar360en2026-09-25T21:41:15.000ZPharmacy ‘at the heart’ of Welsh government’s healthcare prioritieshttps://www.pharmaradar360.com/article/supporting-patients-who-are-clinically-vulnerable-to-covid-19-330ca89993016f45PharmaRadar360en2026-09-25T21:41:15.000ZSupporting patients who are clinically vulnerable to COVID-19https://www.pharmaradar360.com/article/fda-commissioner-nominee-affirms-mmr-vaccine-safety-despite-trump-s-claims-e1569d4826e14760PharmaRadar360en2026-09-25T21:31:56.000ZFDA commissioner nominee affirms MMR vaccine safety despite Trump’s claimshttps://www.pharmaradar360.com/article/here-s-how-much-1000-invested-in-krystal-biotech-5-years-ago-would-be-worth-toda-33624fb55441f011PharmaRadar360en2026-09-25T21:30:24.000ZHere's How Much $1000 Invested In Krystal Biotech 5 Years Ago Would Be Worth Todayhttps://www.pharmaradar360.com/article/krystal-biotech-krys-stock-looks-stretched-against-current-earnings-power-41a3057190af1eb4PharmaRadar360en2026-09-25T21:27:48.000ZKrystal Biotech (KRYS) Stock Looks Stretched Against Current Earnings Powerhttps://www.pharmaradar360.com/article/xenon-s-30-plunge-hides-an-epilepsy-moat-says-biotech-hangout-s-paul-matteis-fb5cf78ea2e8552bPharmaRadar360en2026-09-25T21:08:00.000ZXenon's 30% Plunge Hides an Epilepsy Moat, Says Biotech Hangout's Paul Matteishttps://www.pharmaradar360.com/article/nuevas-convocatorias-de-la-revista-cientifica-anmat-inteligencia-artificial-en-c-00ed4f21feb981ccPharmaRadar360en2026-09-25T21:06:59.000ZNuevas convocatorias de la Revista Científica ANMAT: Inteligencia Artificial en Ciencias Biomédicas y Nanotecnologíahttps://www.pharmaradar360.com/article/fda-nominee-faces-pressure-on-independence-vaccine-safety-31e39264518030baPharmaRadar360en2026-09-25T20:50:45.000ZFDA Nominee Faces Pressure on Independence, Vaccine Safetyhttps://www.pharmaradar360.com/article/ulefnersen-slows-disease-progression-in-phase-3-als-trial-7764ca56678d1f84PharmaRadar360en2026-09-25T20:41:17.000ZUlefnersen slows disease progression in Phase 3 ALS trialhttps://www.pharmaradar360.com/article/egypt-implements-new-economic-framework-for-pharmaceutical-pricing-e9fb11da9de11118PharmaRadar360en2026-09-25T20:36:44.000ZEgypt Implements New Economic Framework for Pharmaceutical Pricinghttps://www.pharmaradar360.com/article/vitamin-c-supplements-tied-to-fewer-deaths-in-blood-disorder-trial-ce51979419b24198PharmaRadar360en2026-09-25T20:32:56.000ZVitamin C Supplements Tied to Fewer Deaths in Blood Disorder Trialhttps://www.pharmaradar360.com/article/ifinatamab-deruxtecan-biologics-license-application-for-certain-patients-with-pr-fdd32384f0449debPharmaRadar360en2026-09-25T20:30:00.000ZIfinatamab Deruxtecan Biologics License Application for Certain Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer Voluntarily Withdrawnhttps://www.pharmaradar360.com/article/biotech-etf-xbi-hits-an-interest-rate-wall-as-40-catalysts-approach-6892588234ed9157PharmaRadar360en2026-09-25T20:19:27.000ZBiotech ETF XBI Hits an Interest Rate Wall as 40+ Catalysts Approachhttps://www.pharmaradar360.com/article/gene-silencing-biotech-adarx-makes-some-noise-with-535m-stock-market-debut-3f23777dd63f10dePharmaRadar360en2026-09-25T19:39:49.000ZGene Silencing-Biotech ADARx Makes Some Noise With $535M Stock Market Debuthttps://www.pharmaradar360.com/article/sanbio-fy2026-q2-earnings-call-25-years-since-founding-first-product-revenue-of-467e21310849ea46PharmaRadar360en2026-09-25T19:34:00.000Z[SanBio FY2026 Q2 Earnings Call] 25 Years Since Founding, First Product Revenue of ¥390 Million with AKUUGO Launch—First Patient Dosing in October, U.S. Phase 3 to Begin Next Fiscal Yearhttps://www.pharmaradar360.com/article/sitc-2026-pre-conference-program-explores-biotech-funding-pitching-and-partnersh-2830973c41044f8ePharmaRadar360en2026-09-25T19:32:28.000ZSITC 2026 Pre-Conference Program Explores Biotech Funding, Pitching, and Partnershipshttps://www.pharmaradar360.com/article/how-early-development-decisions-shape-commercial-readiness-for-biologics-c1e5c43319558596PharmaRadar360en2026-09-25T19:20:35.000ZHow Early Development Decisions Shape Commercial Readiness for Biologicshttps://www.pharmaradar360.com/article/axios-live-sen-todd-young-says-china-s-out-front-on-biomanufacturing-b49284f426081da4PharmaRadar360en2026-09-25T19:15:25.000ZAxios Live: Sen. Todd Young says China's out front on biomanufacturinghttps://www.pharmaradar360.com/article/selected-major-pharmaceutical-policy-events-0ee8a0811c339cdePharmaRadar360en2026-09-25T19:00:11.000ZSelected major pharmaceutical policy events.https://www.pharmaradar360.com/article/titan-pharmaceutical-inc-ttnp-net-income-2024-4-7m-net-loss-up-15-5-691d0ee54d871172PharmaRadar360en2026-09-25T18:53:44.000ZTITAN PHARMACEUTICAL INC (TTNP) Net Income 2024: $4.7M net loss, up 15.5%https://www.pharmaradar360.com/article/titan-pharmaceutical-inc-ttnp-total-assets-2024-2-9m-down-63-9-a782b2e61d657e20PharmaRadar360en2026-09-25T18:52:03.000ZTITAN PHARMACEUTICAL INC (TTNP) Total Assets 2024: $2.9M, down 63.9%https://www.pharmaradar360.com/article/fda-approves-welireg-plus-lenvima-pharmexec-8c55391006ed9467PharmaRadar360en2026-09-25T18:30:15.000ZFDA Approves Welireg Plus Lenvima | PharmExechttps://www.pharmaradar360.com/article/china-expands-its-manufacturing-role-for-biopharma-s-new-drugs-061c904da3b0dd6dPharmaRadar360en2026-09-25T18:23:37.000ZChina expands its manufacturing role for biopharma’s new drugshttps://www.pharmaradar360.com/article/pro-life-groups-urge-fda-to-restore-abortion-pill-safeguards-e2426af77046aa39PharmaRadar360en2026-09-25T17:54:58.000ZPro-Life Groups Urge FDA to Restore Abortion Pill Safeguardshttps://www.pharmaradar360.com/article/cambridge-biotech-co-founded-by-alnylam-founder-maraganore-files-for-ipo-d9376a06cfff0ac8PharmaRadar360en2026-09-25T17:42:00.000ZCambridge biotech co-founded by Alnylam founder Maraganore files for IPOhttps://www.pharmaradar360.com/article/is-the-next-generation-of-chinese-biotech-ready-to-go-global-alone-16f3874a1f435179PharmaRadar360en2026-09-25T16:51:04.000ZIs the next generation of Chinese biotech ready to go global alone?https://www.pharmaradar360.com/article/the-biotech-growth-trust-plc-transaction-in-own-shares-26d78d02c383c40cPharmaRadar360en2026-09-25T16:33:00.000ZThe Biotech Growth Trust PLC - Transaction in Own Shareshttps://www.pharmaradar360.com/article/biotech-stocks-to-research-september-25th-e5e9193f41a03d33PharmaRadar360en2026-09-25T16:26:07.000ZBiotech Stocks To Research - September 25thhttps://www.pharmaradar360.com/article/spdr-s-p-biotech-etf-xbi-stock-price-news-quote-and-history-c496072a78141080PharmaRadar360en2026-09-25T16:17:27.000ZSPDR S&P Biotech ETF (XBI) stock price, news, quote and historyhttps://www.pharmaradar360.com/article/vicapsys-life-sciences-forms-advisory-board-following-stateline-merger-56f7f08bb6f5a3b6PharmaRadar360en2026-09-25T16:02:32.000ZVicapsys Life Sciences Forms Advisory Board Following Stateline Mergerhttps://www.pharmaradar360.com/article/newron-provides-update-on-phase-3-enigma-trs-2-study-fff1b0c9b4486667PharmaRadar360en2026-09-25T15:52:43.000ZNewron Provides Update on Phase 3 ENIGMA-TRS 2 Studyhttps://www.pharmaradar360.com/article/innovation-is-driving-a-new-bull-market-in-biotech-16-ways-to-play-it-from-our-r-f1f9afd0dfc1e9edPharmaRadar360en2026-09-25T15:39:00.000ZInnovation Is Driving a New Bull Market in Biotech. 16 Ways to Play It, From Our Roundtable Experts.https://www.pharmaradar360.com/article/faq-what-comes-next-for-the-340b-rebate-pilot-f6900c9fa2358bd2PharmaRadar360en2026-09-25T15:38:58.000ZFAQ: What Comes Next for the 340B Rebate Pilothttps://www.pharmaradar360.com/article/european-commission-approves-nezglyal-for-rare-brain-disease-c2623348facae534PharmaRadar360en2026-09-25T15:30:56.000ZEuropean Commission approves Nezglyal for rare brain diseasehttps://www.pharmaradar360.com/article/lilly-wins-approval-for-once-weekly-insulin-shot-7c44bd319c61a23fPharmaRadar360en2026-09-25T15:29:43.000ZLilly wins approval for once-weekly insulin shothttps://www.pharmaradar360.com/article/un-high-level-meeting-on-pandemic-prevention-preparedness-and-response-b2a1545f834e1570PharmaRadar360en2026-09-25T15:26:46.000ZUN High-Level Meeting on Pandemic Prevention, Preparedness, and Responsehttps://www.pharmaradar360.com/article/ebola-disease-caused-by-bundibugyo-virus-democratic-republic-of-the-congo-50e21450deb19fcdPharmaRadar360en2026-09-25T15:16:26.000ZEbola disease caused by Bundibugyo virus - Democratic Republic of the Congohttps://www.pharmaradar360.com/article/pharmtech-s-weekly-roundup-september-25-2026-b5fc39bb00930c54PharmaRadar360en2026-09-25T15:14:30.000ZPharmTech’s Weekly Roundup—September 25, 2026https://www.pharmaradar360.com/article/b-riley-s-top-biotech-picks-ahead-of-3q26-earnings-season-21f4b57a11c16fa9PharmaRadar360en2026-09-25T15:14:26.000ZB. Riley’s Top Biotech Picks Ahead of 3Q26 Earnings Seasonhttps://www.pharmaradar360.com/article/weekly-buzz-meso-lly-anip-win-fda-nod-kala-hcti-sign-loi-imvt-halts-lupus-study-83b52857014b8cdbPharmaRadar360en2026-09-25T14:53:00.000ZWeekly Buzz: MESO, LLY, ANIP Win FDA Nod; KALA, HCTI Sign LOI; IMVT Halts Lupus Studyhttps://www.pharmaradar360.com/article/mfn-drug-pricing-won-t-help-but-competition-will-8f6bd219b441a807PharmaRadar360en2026-09-25T14:45:31.000ZMFN Drug Pricing Won’t Help, But Competition Willhttps://www.pharmaradar360.com/article/fda-commissioner-nominee-heidi-overton-is-ignoring-the-science-on-abortion-drug-1a056e8e92e3362ePharmaRadar360en2026-09-25T14:45:05.000ZFDA commissioner nominee Heidi Overton is ignoring the science on abortion drughttps://www.pharmaradar360.com/article/pneumococcal-vaccination-programmes-for-infants-adults-and-individuals-at-increa-8050db2fd0e7d296PharmaRadar360en2026-09-25T14:39:46.000ZPneumococcal vaccination programmes for infants, adults and individuals at increased clinical riskhttps://www.pharmaradar360.com/article/easy-read-guide-to-the-pneumococcal-vaccine-8c98aa2e7ccf2022PharmaRadar360en2026-09-25T14:39:11.000ZEasy Read guide to the pneumococcal vaccinehttps://www.pharmaradar360.com/article/hiv-action-plan-monitoring-and-evaluation-framework-9cb704956fd8cbf0PharmaRadar360en2026-09-25T14:35:37.000ZHIV Action Plan monitoring and evaluation frameworkhttps://www.pharmaradar360.com/article/bristol-myers-squibb-presents-first-data-from-phase-3-excaliber-rrmm-trial-evalu-a5174cf8f58830c5PharmaRadar360en2026-09-25T14:30:12.000ZBristol Myers Squibb Presents First Data From Phase 3 EXCALIBER-RRMM Trial Evaluating Iberdomide Combination in Multiple Myelomahttps://www.pharmaradar360.com/article/movianto-opens-major-pharmaceutical-cold-storage-facility-in-germany-1aeea997cdab52faPharmaRadar360en2026-09-25T14:24:38.000ZMovianto Opens Major Pharmaceutical Cold Storage Facility in Germanyhttps://www.pharmaradar360.com/article/fda-commissioner-pick-pledges-to-follow-statutory-requirements-in-fda-hearing-6bf2c47d70768346PharmaRadar360en2026-09-25T14:15:00.000ZFDA commissioner pick pledges to follow statutory requirements in FDA hearinghttps://www.pharmaradar360.com/article/nanexa-shares-soar-on-1-17-billion-novo-nordisk-deal-for-injection-technology-ca4540a23314bb08PharmaRadar360en2026-09-25T14:14:43.000ZNanexa shares soar on €1.17 billion Novo Nordisk deal for injection technologyhttps://www.pharmaradar360.com/article/adarx-pharmaceuticals-raises-446-million-in-upsized-ipo-e629ef97252c4630PharmaRadar360en2026-09-25T14:07:04.000ZADARx Pharmaceuticals raises $446 million in upsized IPOhttps://www.pharmaradar360.com/article/vicapsys-life-sciences-announces-advisory-board-following-completion-of-statelin-ab434b9c25697d61PharmaRadar360en2026-09-25T14:05:00.000ZVicapsys Life Sciences Announces Advisory Board Following Completion of Stateline Mergerhttps://www.pharmaradar360.com/article/ebitda-per-share-of-teva-pharmaceutical-industries-limited-bsesof-teva-bb0623bc9221f62cPharmaRadar360en2026-09-25T14:04:27.000ZEBITDA per share of Teva Pharmaceutical Industries Limited – BSESOF:TEVAhttps://www.pharmaradar360.com/article/kali-therapeutics-named-to-the-2026-endpoints-11-recognizing-biotech-s-most-prom-74a7f7f08c42a90bPharmaRadar360en2026-09-25T14:01:00.000ZKali Therapeutics Named to the 2026 Endpoints 11, Recognizing Biotech's Most Promising Startupshttps://www.pharmaradar360.com/article/biotech-s-most-exciting-startups-of-2026-meet-this-year-s-endpoints-11-1f64947210f404cePharmaRadar360en2026-09-25T14:00:00.000ZBiotech's most exciting startups of 2026: Meet this year's Endpoints 11https://www.pharmaradar360.com/article/endpoints-news-announces-the-2026-winners-of-the-endpoints-11-awards-showcasing-fc3bb47616ec9a7bPharmaRadar360en2026-09-25T14:00:00.000ZEndpoints News Announces the 2026 Winners of the Endpoints 11 Awards, showcasing biotech’s most exciting startupshttps://www.pharmaradar360.com/article/bristol-myers-squibb-announces-first-presentation-of-results-for-zenbexustm-iber-207c719acf715ab6PharmaRadar360en2026-09-25T14:00:00.000ZBristol Myers Squibb Announces First Presentation of Results for ZENBEXUS™ (iberdomide) in Combination with Daratumumab from Phase 3 EXCALIBER-RRMM Trial in Relapsed or Refractory Multiple Myelomahttps://www.pharmaradar360.com/article/convergesouth-draws-its-largest-crowd-yet-to-winston-salem-with-north-carolina-b-a0deefed0c501d10PharmaRadar360en2026-09-25T13:57:11.000ZConvergeSouth Draws Its Largest Crowd Yet to Winston-Salem, With North Carolina Biotech in the Spotlighthttps://www.pharmaradar360.com/article/longevity-biotech-s-617billion-opportunity-longevity-news-roundup-week-39-2026-a4efa343bee041fcPharmaRadar360en2026-09-25T13:52:59.000ZLongevity Biotech’s $617Billion Opportunity | Longevity News Roundup — Week 39, 2026https://www.pharmaradar360.com/article/ecoceres-supports-astrazeneca-s-net-zero-journey-with-first-hvo-application-in-c-54be299a0feb5eddPharmaRadar360en2026-09-25T13:41:35.000ZEcoCeres supports AstraZeneca’s net-zero journey with first HVO application in China’s pharmaceutical sectorhttps://www.pharmaradar360.com/article/adarx-raises-446m-in-biotech-s-third-largest-ipo-of-2026-city-files-to-go-public-1ed124e1049c5e15PharmaRadar360en2026-09-25T13:39:27.000ZADARx raises $446M in biotech’s third largest IPO of 2026, City files to go publichttps://www.pharmaradar360.com/article/fierce-pharma-asia-lilly-s-3-35b-innocare-deal-korea-s-breakthrough-china-s-5-ye-044c28fe098dc5e6PharmaRadar360en2026-09-25T13:38:04.000ZFierce Pharma Asia—Lilly’s $3.35B InnoCare deal; Korea’s breakthrough; China’s 5-year biotech planhttps://www.pharmaradar360.com/article/kobayashi-in-500-billion-buyout-talks-after-red-yeast-case-415a1d65abcc4062PharmaRadar360en2026-09-25T13:37:35.000ZKobayashi in ¥500 billion buyout talks after red-yeast casehttps://www.pharmaradar360.com/article/why-retail-pharmacy-s-trust-challenge-is-also-its-path-forward-e2b0702c8d08029bPharmaRadar360en2026-09-25T13:28:02.000ZWhy Retail Pharmacy’s Trust Challenge Is Also Its Path Forwardhttps://www.pharmaradar360.com/article/biotech-pre-market-movers-aiff-jagx-surge-cdt-gctk-slide-d30c867d6ba2929ePharmaRadar360en2026-09-25T13:24:00.000ZBiotech Pre-Market Movers: AIFF, JAGX Surge; CDT, GCTK Slidehttps://www.pharmaradar360.com/article/cphi-milan-usp-benchmarks-reshape-procurement-incentives-1d09ef64bee6e38bPharmaRadar360en2026-09-25T13:15:16.000ZCPHI Milan: USP Benchmarks Reshape Procurement Incentiveshttps://www.pharmaradar360.com/article/movianto-opens-one-of-europe-s-largest-pharmaceutical-logistics-hub-e13951088a73e86fPharmaRadar360en2026-09-25T13:13:51.000ZMovianto opens one of Europe's largest pharmaceutical logistics hubhttps://www.pharmaradar360.com/article/new-graft-versus-host-disease-treatments-what-s-in-the-biotech-pipeline-in-2026-916b9bd374d9f453PharmaRadar360en2026-09-25T13:01:39.000ZNew Graft-versus-Host Disease treatments: What’s in the biotech pipeline in 2026?https://www.pharmaradar360.com/article/italy-s-reported-first-psychedelic-trial-for-hard-to-treat-depression-will-inclu-52166ac52bd4d21fPharmaRadar360en2026-09-25T12:48:00.000ZItaly's reported first psychedelic trial for hard-to-treat depression will include more people.https://www.pharmaradar360.com/article/fda-approves-welireg-and-lenvima-combo-for-advanced-kidney-cancer-004774cf23718913PharmaRadar360en2026-09-25T12:45:00.000ZFDA approves Welireg and Lenvima combo for advanced kidney cancerhttps://www.pharmaradar360.com/article/sanofi-aventis-canada-inc-recalling-certain-insulin-pens-and-cartridges-57d08a4b5c103889PharmaRadar360en2026-09-25T12:00:00.000ZSanofi-Aventis Canada Inc. recalling certain insulin pens and cartridgeshttps://www.pharmaradar360.com/article/perma-handtm-silk-suture-bcb56fa36b10c35fPharmaRadar360en2026-09-25T12:00:00.000ZPERMA-HAND™ Silk Suturehttps://www.pharmaradar360.com/article/limited-number-of-sarclisa-single-use-vials-may-have-been-frozen-during-shipment-7434ecaa767510a3PharmaRadar360en2026-09-25T12:00:00.000ZLimited number of Sarclisa single use vials may have been frozen during shipmenthttps://www.pharmaradar360.com/article/amplatzertm-amulettm-left-atrial-appendage-occluder-4548369052f42f94PharmaRadar360en2026-09-25T12:00:00.000ZAmplatzer™ Amulet™ Left Atrial Appendage Occluderhttps://www.pharmaradar360.com/article/endpoints-news-hires-reuters-correspondent-maggie-fick-to-cover-u-s-pharma-ac4ed419dd313f6cPharmaRadar360en2026-09-25T11:57:03.000ZEndpoints News Hires Reuters Correspondent Maggie Fick to Cover U.S. Pharmahttps://www.pharmaradar360.com/article/cordis-project-robotic-endovascular-access-for-critical-treatment-ec96d2bc8d2fff8fPharmaRadar360en2026-09-25T11:46:15.000ZCORDIS project: Robotic Endovascular Access for Critical Treatmenthttps://www.pharmaradar360.com/article/cordis-project-biological-permeation-enhancers-for-transbuccal-drug-delivery-f903b39bcb8a3170PharmaRadar360en2026-09-25T11:46:09.000ZCORDIS project: Biological permeation enhancers for transbuccal drug deliveryhttps://www.pharmaradar360.com/article/cordis-project-the-first-personalized-precision-digital-intervention-in-a-video-b11922c4cc6a045aPharmaRadar360en2026-09-25T11:46:09.000ZCORDIS project: The first personalized, precision digital intervention in a video-game therapeutic for depressionhttps://www.pharmaradar360.com/article/cordis-project-directed-evolution-to-understand-and-engineer-bioactive-long-nonc-267f4cef2ae7db76PharmaRadar360en2026-09-25T11:46:07.000ZCORDIS project: Directed Evolution to Understand and Engineer Bioactive Long Noncoding RNAshttps://www.pharmaradar360.com/article/legend-biotech-reports-5-year-carvykti-data-in-myeloma-patients-df8b969fbedfd4abPharmaRadar360en2026-09-25T11:28:49.000ZLegend Biotech reports 5-year CARVYKTI data in myeloma patientshttps://www.pharmaradar360.com/article/legend-biotech-reports-five-year-cartitude-2-data-showing-durable-treatment-free-2cdf62d76e1caf6ePharmaRadar360en2026-09-25T11:11:00.000ZLegend Biotech Reports Five-Year CARTITUDE-2 Data Showing Durable Treatment-Free Remission With CARVYKTI in Earlier-Line Multiple Myelomahttps://www.pharmaradar360.com/article/legend-biotech-presents-carvykti-data-showing-half-of-patients-with-rrmm-remaine-ff4a6ffb89197ecbPharmaRadar360en2026-09-25T11:07:48.000ZLegend Biotech Presents CARVYKTI Data Showing Half of Patients with RRMM Remained Progression-Free and Alive Five Years After a Single Infusionhttps://www.pharmaradar360.com/article/aurion-biotech-completes-enrollment-in-phase-3-astra-study-of-aurn001-for-cornea-793eaa6eb89c9b72PharmaRadar360en2026-09-25T11:06:04.000ZAurion Biotech completes enrollment in phase 3 ASTRA study of AURN001 for corneal edema secondary to corneal endothelial dysfunctionhttps://www.pharmaradar360.com/article/the-next-alnylam-rnai-biotech-city-therapeutics-files-for-ipo-48715f4874cf4d45PharmaRadar360en2026-09-25T11:04:00.000ZThe next Alnylam? RNAi biotech City Therapeutics files for IPOhttps://www.pharmaradar360.com/article/roche-and-earendil-forge-1-5bn-bispecific-discovery-deal-63a03f3822c118f0PharmaRadar360en2026-09-25T11:01:21.000ZRoche and Earendil forge $1.5bn bispecific discovery dealhttps://www.pharmaradar360.com/article/half-of-20-blood-cancer-patients-were-alive-with-no-cancer-progression-or-furthe-93634d310aa07310PharmaRadar360en2026-09-25T11:00:00.000ZHalf of 20 blood cancer patients were alive, with no cancer progression or further treatment, five years after one infusion.https://www.pharmaradar360.com/article/are-electronic-prescribing-systems-as-safe-as-we-think-12bd8c34773b70f3PharmaRadar360en2026-09-25T10:59:18.000ZAre electronic prescribing systems as safe as we think?https://www.pharmaradar360.com/article/u-s-fda-approves-welireg-belzutifan-plus-lenvima-lenvatinib-for-certain-previous-83acca6a2792462aPharmaRadar360en2026-09-25T10:45:00.000ZU.S. FDA Approves WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) for Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC)https://www.pharmaradar360.com/article/jusvinza-demonstrates-efficacy-against-chikungunya-6d6d32c7c91d7f05PharmaRadar360en2026-09-25T10:43:22.000ZJusvinza Demonstrates Efficacy Against Chikungunyahttps://www.pharmaradar360.com/article/find-product-information-about-medicines-985a650e836aba64PharmaRadar360en2026-09-25T10:32:59.000ZFind product information about medicineshttps://www.pharmaradar360.com/article/novo-does-another-small-deal-this-time-with-drug-delivery-biotech-nanexa-7af623e602aaf0f3PharmaRadar360en2026-09-25T10:29:00.000ZNovo does another small deal, this time with drug delivery biotech Nanexahttps://www.pharmaradar360.com/article/safer-radiotherapy-triannual-event-analysis-and-learning-e491d544e5e562baPharmaRadar360en2026-09-25T10:20:59.000ZSafer radiotherapy: triannual event analysis and learninghttps://www.pharmaradar360.com/article/can-legend-biotech-legn-turn-cell-therapy-scale-into-compounding-wealth-9cd9384b41318f65PharmaRadar360en2026-09-25T10:06:04.000ZCan Legend Biotech (LEGN) Turn Cell Therapy Scale Into Compounding Wealth?https://www.pharmaradar360.com/article/fda-nominee-faces-bipartisan-scrutiny-over-vaccines-and-abortion-drug-981d4c9267bd431fPharmaRadar360en2026-09-25T10:00:00.000ZFDA nominee faces bipartisan scrutiny over vaccines and abortion drughttps://www.pharmaradar360.com/article/dispatches-from-cgt-international-big-pharma-m-a-is-the-new-biotech-ipo-c9b1d472ba4b94cfPharmaRadar360en2026-09-25T09:59:04.000ZDispatches from CGT International: Big pharma M&A is the new biotech IPOhttps://www.pharmaradar360.com/article/phoenix-quad-c-thoma-bravo-target-occupational-health-pharmaceutical-growth-driv-2a771b66ec7f2301PharmaRadar360en2026-09-25T09:38:09.000ZPhoenix, Quad-C, Thoma Bravo target occupational health; Pharmaceutical growth drives May River’s sale of Dickson to Blackstone and Copelandhttps://www.pharmaradar360.com/article/why-biotech-is-becoming-essential-to-the-future-of-food-and-how-ai-is-accelerati-cd444053f8da00cdPharmaRadar360en2026-09-25T08:58:25.000ZWhy biotech is becoming essential to the future of food – and how AI is accelerating the journeyhttps://www.pharmaradar360.com/article/novo-inks-1-3b-nanexa-deal-to-unlock-long-acting-obesity-injectables-a881a2e28ecbc524PharmaRadar360en2026-09-25T08:53:48.000ZNovo inks $1.3B Nanexa deal to unlock long-acting obesity injectableshttps://www.pharmaradar360.com/article/wnt-drug-gives-msd-first-eye-disease-win-after-eyebio-deal-c83e09dee95e6dcfPharmaRadar360en2026-09-25T08:48:21.000ZWnt drug gives MSD first eye disease win after EyeBio dealhttps://www.pharmaradar360.com/article/auburn-native-s-biotech-company-goes-public-it-s-incredibly-rewarding-d118005799e1566dPharmaRadar360en2026-09-25T08:45:00.000ZAuburn native's biotech company goes public: 'It's incredibly rewarding'https://www.pharmaradar360.com/article/biotech-stocks-at-52-week-highs-cdna-13-gral-15-twst-16-adpt-rvty-41820e80afb11d18PharmaRadar360en2026-09-25T08:39:00.000ZBiotech Stocks At 52-Week Highs - CDNA +13%, GRAL +15%, TWST +16%, ADPT, RVTYhttps://www.pharmaradar360.com/article/trump-pick-to-lead-fda-questioned-by-us-senate-da9afb42dd1ba14bPharmaRadar360en2026-09-25T08:22:00.000ZTrump pick to lead FDA questioned by US Senatehttps://www.pharmaradar360.com/article/msd-s-eye-drug-meets-primary-endpoint-in-trial-de38639efd712b58PharmaRadar360en2026-09-25T08:05:00.000ZMSD’s eye drug meets primary endpoint in trialhttps://www.pharmaradar360.com/article/confirmatory-trials-and-the-new-realities-of-fda-expedited-approval-6cd33a2239afedccPharmaRadar360en2026-09-25T07:57:26.000ZConfirmatory trials and the new realities of FDA expedited approvalhttps://www.pharmaradar360.com/article/teclistamab-plus-daratumumab-shows-18-point-survival-gain-at-3-years-in-multiple-5f53bbf58e19036bPharmaRadar360en2026-09-25T07:48:29.000ZTeclistamab plus daratumumab shows 18-point survival gain at 3 years in multiple myelomahttps://www.pharmaradar360.com/article/atyr-pharma-reaches-fda-protocol-agreement-for-efzofitimod-phase-3-trial-ff90d06e40159c37PharmaRadar360en2026-09-25T07:48:29.000ZaTyr Pharma Reaches FDA Protocol Agreement for Efzofitimod Phase 3 Trialhttps://www.pharmaradar360.com/article/adarx-prices-446-3m-nasdaq-debut-continuing-industry-s-ipo-momentum-bf62d46d4f4c34c2PharmaRadar360en2026-09-25T07:46:00.000ZADARx prices $446.3M Nasdaq debut, continuing industry’s IPO momentumhttps://www.pharmaradar360.com/article/sls-stock-hits-over-3-year-high-as-aml-drug-trial-nears-final-readout-wall-stree-d690b1c596b74875PharmaRadar360en2026-09-25T07:41:25.000ZSLS Stock Hits Over 3-Year High As AML Drug Trial Nears Final Readout — Wall Street Sees 30% More Upsidehttps://www.pharmaradar360.com/article/roche-pays-atavistik-bio-usd-70m-upfront-in-research-partnership-3aae3741cae97a47PharmaRadar360en2026-09-25T07:36:46.000ZRoche pays Atavistik Bio USD 70m upfront in research partnershiphttps://www.pharmaradar360.com/article/kobayashi-in-3-2-billion-buyout-talks-after-red-yeast-case-915308a75717f883PharmaRadar360en2026-09-25T07:34:47.000ZKobayashi in $3.2 Billion Buyout Talks After Red-Yeast Casehttps://www.pharmaradar360.com/article/the-cd47-signal-that-oncology-trial-designers-are-misreading-e7b943df4346729dPharmaRadar360en2026-09-25T07:33:29.000ZThe CD47 Signal That Oncology Trial Designers Are Misreadinghttps://www.pharmaradar360.com/article/cryoport-strong-pipeline-of-cell-and-gene-therapy-approvals-nasdaq-cyrx-61f64e59e3b25d5aPharmaRadar360en2026-09-25T07:26:56.000ZCryoport: Strong Pipeline Of Cell And Gene Therapy Approvals (NASDAQ:CYRX)https://www.pharmaradar360.com/article/is-it-smart-to-buy-aska-pharmaceutical-holdings-co-ltd-tse-4886-before-it-goes-e-3f677d584b0cf63bPharmaRadar360en2026-09-25T07:17:18.000ZIs It Smart To Buy ASKA Pharmaceutical Holdings Co.,Ltd. (TSE:4886) Before It Goes Ex-Dividend?https://www.pharmaradar360.com/article/the-pre-cision-platform-wins-research-and-development-achievement-award-from-pha-32dde6afcca1bf48PharmaRadar360en2026-09-25T07:09:46.000ZThe pre|CISION® Platform Wins Research and Development Achievement Award from Pharma Industry Awards UK 2026https://www.pharmaradar360.com/article/black-hawk-locks-in-meteora-financing-for-vesicor-biotech-merger-59ec0fc485d3bbaaPharmaRadar360en2026-09-25T07:04:45.000ZBlack Hawk locks in Meteora financing for Vesicor biotech mergerhttps://www.pharmaradar360.com/article/adarx-scores-upsized-446m-ipo-while-city-maps-out-nasdaq-plans-27b8fac812a355c8PharmaRadar360en2026-09-25T06:46:52.000ZADARx scores upsized $446M IPO, while City maps out Nasdaq planshttps://www.pharmaradar360.com/article/acadia-reports-phase-2-results-for-remlifanserin-in-alzheimer-s-disease-psychosi-c74361f0213b1564PharmaRadar360en2026-09-25T06:43:28.000ZAcadia Reports Phase 2 Results for Remlifanserin in Alzheimer’s Disease Psychosishttps://www.pharmaradar360.com/article/kyverna-reports-one-year-miv-cel-data-in-stiff-person-syndrome-gmg-624d0813a544aea2PharmaRadar360en2026-09-25T06:43:28.000ZKyverna Reports One-Year miv-cel Data in Stiff Person Syndrome, gMGhttps://www.pharmaradar360.com/article/sefaxersen-meets-primary-endpoint-in-phase-3-iga-nephropathy-trial-517888a3e70e4a9cPharmaRadar360en2026-09-25T06:43:28.000ZSefaxersen Meets Primary Endpoint in Phase 3 IgA Nephropathy Trialhttps://www.pharmaradar360.com/article/biotech-us-house-and-senate-propose-2-bills-for-cisa-to-step-up-the-protection-o-75a015ecbb7d07ecPharmaRadar360en2026-09-25T06:23:38.000ZBiotech: US House and Senate propose 2 bills for CISA to step up the protection of biotechnology infrastructurehttps://www.pharmaradar360.com/article/big-read-big-pharma-bets-billions-on-china-biotech-will-washington-pull-the-plug-0756239395352f22PharmaRadar360en2026-09-25T06:19:19.000Z[Big read] Big Pharma bets billions on China biotech — will Washington pull the plug?https://www.pharmaradar360.com/article/big-read-big-pharma-bets-billions-on-china-biotech-will-washington-pull-the-plug-3511dc5fb4bbb15aPharmaRadar360en2026-09-25T06:19:18.000Z[Big read] Big Pharma bets billions on China biotech — will Washington pull the plug?https://www.pharmaradar360.com/article/the-focus-01-clinical-trial-design-and-preclinical-data-further-demonstrate-the-0802ba0230a00153PharmaRadar360en2026-09-25T06:01:23.000ZThe FOCUS-01 Clinical Trial Design and Preclinical Data Further Demonstrate the Potential of AVA6103 at AACR Conference on Pancreatic Cancerhttps://www.pharmaradar360.com/article/santen-pharmaceutical-tse-4536-could-be-a-buy-for-its-upcoming-dividend-211ec25c526845c1PharmaRadar360en2026-09-25T05:59:24.000ZSanten Pharmaceutical (TSE:4536) Could Be A Buy For Its Upcoming Dividendhttps://www.pharmaradar360.com/article/why-it-might-not-make-sense-to-buy-kyorin-pharmaceutical-co-ltd-tse-4569-for-its-b0042c5cef02d226PharmaRadar360en2026-09-25T05:50:54.000ZWhy It Might Not Make Sense To Buy KYORIN Pharmaceutical Co., Ltd. (TSE:4569) For Its Upcoming Dividendhttps://www.pharmaradar360.com/article/moderna-begins-phase-1-clinical-trial-of-ebola-vaccine-against-strain-behind-drc-0f15edae8af6e558PharmaRadar360en2026-09-25T04:42:56.000ZModerna begins Phase 1 clinical trial of Ebola vaccine against strain behind DRC outbreakhttps://www.pharmaradar360.com/article/health-brief-the-tightrope-faced-by-trump-s-fda-pick-5298af1eb3d49489PharmaRadar360en2026-09-25T04:34:24.000ZHealth Brief: The tightrope faced by Trump’s FDA pickhttps://www.pharmaradar360.com/article/movianto-opens-30-000-sqm-pharmaceutical-logistics-hub-in-germany-06c67aeac3bd7d82PharmaRadar360en2026-09-25T04:00:39.000ZMovianto opens 30,000-sqm pharmaceutical logistics hub in Germanyhttps://www.pharmaradar360.com/article/angiographic-catheter-recall-boston-scientific-removes-imager-ii-angiographic-ca-7806189c7e5eea8cPharmaRadar360en2026-09-25T04:00:00.000ZAngiographic Catheter Recall: Boston Scientific Removes Imager II Angiographic Cathetershttps://www.pharmaradar360.com/article/mrna-on-track-to-be-september-s-no-2-s-p-500-stock-but-these-5-smaller-health-ca-aae5b19ae2ba20e5PharmaRadar360en2026-09-25T03:23:36.000ZMRNA On Track To Be September's No. 2 S&P 500 Stock — But These 5 Smaller Health Care Names Did Even Betterhttps://www.pharmaradar360.com/article/mrna-on-track-to-be-september-s-no-2-s-p-500-stock-but-these-5-smaller-health-ca-c11e7e5386621baaPharmaRadar360en2026-09-25T03:23:00.000ZMRNA On Track To Be September's No. 2 S&P 500 Stock — But These 5 Smaller Health Care Names Did Even Betterhttps://www.pharmaradar360.com/article/sunhawk-vision-biotech-inc-cash-flow-tpex-7759-7c6d9d5bf85008f9PharmaRadar360en2026-09-25T02:21:46.000ZSunhawk Vision Biotech, Inc. Cash Flow – TPEX:7759https://www.pharmaradar360.com/article/young-discusses-american-biotech-leadership-at-axios-live-event-7d6d523c5d4a26a9PharmaRadar360en2026-09-25T01:26:29.000ZYoung Discusses American Biotech Leadership at Axios Live Eventhttps://www.pharmaradar360.com/article/adrx-ipo-news-sirna-biotech-adarx-pharmaceuticals-prices-upsized-ipo-at-17-the-h-b33fc17edd8dc0b6PharmaRadar360en2026-09-25T00:53:00.000ZADRX IPO News - siRNA biotech ADARx Pharmaceuticals prices upsized IPO at $17, the high end of the rangehttps://www.pharmaradar360.com/article/veraxa-biotech-vrxa-advances-oncology-pipeline-as-xlife-sciences-reports-first-h-4e1dcb90c50a16abPharmaRadar360en2026-09-25T00:40:35.000ZVERAXA Biotech (VRXA) Advances Oncology Pipeline as Xlife Sciences Reports First-Half Progresshttps://www.pharmaradar360.com/article/rnai-drug-specialist-adarx-raises-446m-ipo-bbfd6fd6937188fbPharmaRadar360en2026-09-25T00:37:33.000ZRNAi drug specialist ADARx raises $446M IPOhttps://www.pharmaradar360.com/article/otsuka-foods-to-revise-prices-of-some-products-new-prices-to-take-effect-with-de-dae178c5cb3b056cPharmaRadar360en2026-09-25T00:00:00.000ZOtsuka Foods to Revise Prices of Some Products New Prices to Take Effect with Deliveries as of January 1, 2027https://www.pharmaradar360.com/article/medicaid-and-children-s-health-insurance-program-chip-generic-information-collec-a517ce386e9bcc9aPharmaRadar360en2026-09-25T00:00:00.000ZMedicaid and Children's Health Insurance Program (CHIP) Generic Information Collection Activities: Proposed Collection; Comment Requesthttps://www.pharmaradar360.com/article/draft-nih-policy-on-sharing-summary-level-study-results-with-clinical-research-p-91eacb94fe96ce62PharmaRadar360en2026-09-25T00:00:00.000ZDraft NIH Policy on Sharing Summary Level Study Results With Clinical Research Participantshttps://www.pharmaradar360.com/article/robotically-assisted-surgical-devices-premarket-submissions-draft-guidance-for-i-f617f9d98de05341PharmaRadar360en2026-09-25T00:00:00.000ZRobotically-Assisted Surgical Devices-Premarket Submissions; Draft Guidance for Industry and Food and Drug Administration Staff; Availabilityhttps://www.pharmaradar360.com/article/dermatologic-and-ophthalmic-drugs-advisory-committee-notice-of-meeting-establish-e70cef7ecba8973bPharmaRadar360en2026-09-25T00:00:00.000ZDermatologic and Ophthalmic Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-New Drug Application (NDA) 219694 for Atropine Sulfate Ophthalmic Solution, 0.01%https://www.pharmaradar360.com/article/reauthorization-of-the-biosimilar-user-fee-act-public-meeting-request-for-commen-e1de7e5e0a4360e9PharmaRadar360en2026-09-25T00:00:00.000ZReauthorization of the Biosimilar User Fee Act; Public Meeting; Request for Commentshttps://www.pharmaradar360.com/article/filing-of-color-additive-petition-from-doehler-gmbh-request-to-amend-the-color-a-fa83a20668624e42PharmaRadar360en2026-09-25T00:00:00.000ZFiling of Color Additive Petition From Doehler GmbH; Request To Amend the Color Additive Regulations To Provide for the Safe Use of Calcium Sulfate in Various Foods at Levels Consistent With Good Manufacturing Practicehttps://www.pharmaradar360.com/article/food-additives-permitted-for-direct-addition-to-food-for-human-consumption-vitam-4f95d0d5dc7d090ePharmaRadar360en2026-09-25T00:00:00.000ZFood Additives Permitted for Direct Addition to Food for Human Consumption; Vitamin D2 Inactive Bakers Yeasthttps://www.pharmaradar360.com/article/jeffrey-thies-final-debarment-order-3892b6ffea2019a7PharmaRadar360en2026-09-25T00:00:00.000ZJeffrey Thies: Final Debarment Orderhttps://www.pharmaradar360.com/article/naveed-aslam-final-debarment-order-93b24598baec685ePharmaRadar360en2026-09-25T00:00:00.000ZNaveed Aslam: Final Debarment Orderhttps://www.pharmaradar360.com/article/privacy-act-of-1974-matching-program-77516d93d671562ePharmaRadar360en2026-09-25T00:00:00.000ZPrivacy Act of 1974; Matching Programhttps://www.pharmaradar360.com/article/six-cleveland-clinic-hospitals-recognized-as-top-performers-by-vizient-0f6d6d965abc6e20PharmaRadar360en2026-09-25T00:00:00.000ZSix Cleveland Clinic Hospitals Recognized as Top Performers by Vizienthttps://www.pharmaradar360.com/article/scaling-back-screen-time-during-school-year-40c09147c29d6937PharmaRadar360en2026-09-25T00:00:00.000ZScaling Back Screen Time During School Yearhttps://www.pharmaradar360.com/article/cost-effectiveness-and-value-implications-of-veligrotug-versus-teprotumumab-for-7ece3f4eda8bff11PharmaRadar360en2026-09-25T00:00:00.000ZCost-effectiveness and value implications of veligrotug versus teprotumumab for moderate-to-severe thyroid eye disease in the United States.https://www.pharmaradar360.com/article/retained-root-fragments-following-exodontia-a-narrative-review-of-clinical-outco-9379bf909d7708cdPharmaRadar360en2026-09-25T00:00:00.000ZRetained Root Fragments Following Exodontia: A Narrative Review of Clinical outcomes, Risk-Based Management, and the Ethico-Legal Standard of Disclosurehttps://www.pharmaradar360.com/article/debriefing-characteristics-associated-with-the-development-of-clinical-judgment-52584a8e15933521PharmaRadar360en2026-09-25T00:00:00.000ZDebriefing Characteristics Associated With the Development of Clinical Judgment in Nursing Studentshttps://www.pharmaradar360.com/article/precision-periodontology-promise-practicality-and-clinical-reality-1e0dfc4f5dbe38f0PharmaRadar360en2026-09-25T00:00:00.000ZPrecision Periodontology: Promise, Practicality and Clinical Realityhttps://www.pharmaradar360.com/article/predictive-factors-for-hemoglobin-decrease-after-simple-open-prostatectomy-singl-5786a2682345ae91PharmaRadar360en2026-09-25T00:00:00.000ZPredictive Factors for Hemoglobin Decrease After Simple Open Prostatectomy: Single-center Clinical Experiencehttps://www.pharmaradar360.com/article/understanding-gender-dysphoria-through-diverse-clinical-presentations-6af452b0df960475PharmaRadar360en2026-09-25T00:00:00.000ZUnderstanding gender dysphoria through diverse clinical presentationshttps://www.pharmaradar360.com/article/effectiveness-and-safety-of-ultrasound-guided-quadratus-lumborum-block-combined-31384ddc215f7dd5PharmaRadar360en2026-09-25T00:00:00.000ZEffectiveness and safety of ultrasound-guided quadratus lumborum block combined with low-dose spinal anesthesia &lt;i&gt;versus&lt;/i&gt; general anesthesia in percutaneous nephrolithotomy: a randomized controlled trialhttps://www.pharmaradar360.com/article/the-social-architecture-of-participation-7b1cd5b917b0f0daPharmaRadar360en2026-09-25T00:00:00.000ZThe Social Architecture of Participationhttps://www.pharmaradar360.com/article/targeting-a-moving-threshold-antigen-density-as-a-design-constraint-for-particul-fe54455bb8a0b1f9PharmaRadar360en2026-09-25T00:00:00.000ZTargeting a Moving Threshold: Antigen Density as a Design Constraint for Particulate Drug Delivery in HER2-Low and HER2-Ultralow Breast Cancer—A Narrative Reviewhttps://www.pharmaradar360.com/article/the-challenge-of-treating-syringomyelia-associated-with-extensive-arachnoiditis-74de3063e7988678PharmaRadar360en2026-09-25T00:00:00.000ZThe Challenge of Treating Syringomyelia Associated with Extensive Arachnoiditishttps://www.pharmaradar360.com/article/nod2-variants-and-duration-of-hospitalization-after-endoscopic-treatment-of-bili-fff75a7aa65897ebPharmaRadar360en2026-09-25T00:00:00.000ZNOD2 Variants and Duration of Hospitalization After Endoscopic Treatment of Biliary Strictures Following Liver Transplantation: A Cutoff-Dependent Associationhttps://www.pharmaradar360.com/article/dynamic-changes-in-serum-neutrophil-gelatinase-associated-lipocalin-for-discrimi-82b06f23ed85e2efPharmaRadar360en2026-09-25T00:00:00.000ZDynamic Changes in Serum Neutrophil Gelatinase-Associated Lipocalin for Discrimination of Creatinine-Defined Acute Kidney Injury After Laparoscopic Sleeve Gastrectomy: A Prospective Observational Cohort Studyhttps://www.pharmaradar360.com/article/retrospective-assessment-of-llm-decision-making-for-iol-power-selection-in-catar-8e2149ab35ed73e5PharmaRadar360en2026-09-25T00:00:00.000ZRetrospective Assessment of LLM Decision-Making for IOL Power Selection in Cataract Surgery in Comparison with Surgeon Performancehttps://www.pharmaradar360.com/article/multimodality-imaging-of-mitral-regurgitation-2f6766a1086173c4PharmaRadar360en2026-09-25T00:00:00.000ZMultimodality Imaging of Mitral Regurgitationhttps://www.pharmaradar360.com/article/bullying-and-cyberbullying-in-childhood-and-adolescence-a-narrative-review-and-p-76e3cd8ef6e55b2ePharmaRadar360en2026-09-25T00:00:00.000ZBullying and Cyberbullying in Childhood and Adolescence: A Narrative Review and Proposed Clinical Response Frameworkhttps://www.pharmaradar360.com/article/validation-of-the-hungarian-fad-gf-and-baffs-in-a-multi-informant-clinical-sampl-3fe5b25c797bd30dPharmaRadar360en2026-09-25T00:00:00.000ZValidation of the Hungarian FAD-GF and BAFFS in a Multi-Informant Clinical Sample of Families of Adolescentshttps://www.pharmaradar360.com/article/vermicomposting-reshapes-microbial-communities-and-functional-potential-in-sewag-ae6e64b6b8199af4PharmaRadar360en2026-09-25T00:00:00.000ZVermicomposting Reshapes Microbial Communities and Functional Potential in Sewage Sludge: Insights from 16S and ITS Metabarcodinghttps://www.pharmaradar360.com/article/choriocapillaris-dysfunction-in-retinal-diseases-multimodal-imaging-biomarkers-p-4b51271ff5f4702bPharmaRadar360en2026-09-25T00:00:00.000ZChoriocapillaris Dysfunction in Retinal Diseases: Multimodal Imaging Biomarkers, Pathophysiological Insights, and Emerging Clinical Applicationshttps://www.pharmaradar360.com/article/phenotypic-divergence-among-genomically-closely-related-klebsiella-pneumoniae-cl-d785ff96c21dac46PharmaRadar360en2026-09-25T00:00:00.000ZPhenotypic Divergence Among Genomically Closely Related Klebsiella pneumoniae Clinical Isolateshttps://www.pharmaradar360.com/article/feasibility-of-a-teacher-supervised-chatgpt-assisted-workflow-for-individualized-3e57e1bd3fbefb65PharmaRadar360en2026-09-25T00:00:00.000ZFeasibility of a teacher-supervised ChatGPT-assisted workflow for individualized exercise planning in university physical education: a two-phase study using a fuzzy Delphi process and a cluster pilot trialhttps://www.pharmaradar360.com/article/correction-clinical-relevance-of-loneliness-in-the-treatment-of-depression-study-488121acc67451a2PharmaRadar360en2026-09-25T00:00:00.000ZCorrection: Clinical relevance of loneliness in the treatment of depression: study protocol for a naturalistic prospective longitudinal studyhttps://www.pharmaradar360.com/article/added-effects-of-dual-task-water-based-exercise-on-global-cognition-and-physical-d78831b4678fef85PharmaRadar360en2026-09-25T00:00:00.000ZAdded effects of dual-task water-based exercise on global cognition and physical performance in older women: a three-arm randomized controlled trialhttps://www.pharmaradar360.com/article/cannabinoids-in-hematologic-malignancies-mechanisms-and-therapeutic-potential-fo-455ec19e5f96dc3dPharmaRadar360en2026-09-25T00:00:00.000ZCannabinoids in hematologic malignancies: mechanisms and therapeutic potential for overcoming drug resistancehttps://www.pharmaradar360.com/article/real-world-clinical-outcomes-and-safety-of-anlotinib-containing-regimens-in-pedi-730b69bf7352220bPharmaRadar360en2026-09-25T00:00:00.000ZReal-world clinical outcomes and safety of anlotinib-containing regimens in pediatric solid tumors: a retrospective cohort study at a Chinese centerhttps://www.pharmaradar360.com/article/transcutaneous-auricular-vagus-nerve-stimulation-tavns-a-comprehensive-review-of-3a56ae80f15917b1PharmaRadar360en2026-09-25T00:00:00.000ZTranscutaneous auricular vagus nerve stimulation (taVNS): a comprehensive review of mechanisms, clinical applications, and future directionshttps://www.pharmaradar360.com/article/effects-of-12-week-24-form-tai-chi-on-cognitive-function-cerebral-perfusion-and-3074684e688c186cPharmaRadar360en2026-09-25T00:00:00.000ZEffects of 12-week 24-form Tai Chi on cognitive function, cerebral perfusion, and vascular function in postmenopausal women with mild cognitive impairment: an exploratory randomized controlled trialhttps://www.pharmaradar360.com/article/delayed-diagnosis-of-selected-thoracic-and-mediastinal-conditions-in-young-adult-8b5dc28ca3ef2176PharmaRadar360en2026-09-25T00:00:00.000ZDelayed diagnosis of selected thoracic and mediastinal conditions in young adults: a focused narrative review of clinical pitfalls, cognitive biases, and system barriershttps://www.pharmaradar360.com/article/editorial-new-concepts-advances-and-future-trends-in-clinical-research-on-eye-di-a57c8623c59995e7PharmaRadar360en2026-09-25T00:00:00.000ZEditorial: New concepts, advances, and future trends in clinical research on eye diseaseshttps://www.pharmaradar360.com/article/clinical-manifestations-and-proportions-of-severe-outcomes-in-pediatric-acute-po-554128e88e8ff456PharmaRadar360en2026-09-25T00:00:00.000ZClinical manifestations and proportions of severe outcomes in pediatric acute post-streptococcal glomerulonephritis: a systematic review and meta-analysis of predominantly hospital-based cohortshttps://www.pharmaradar360.com/article/deproteinized-calf-blood-extract-with-or-without-punctal-plugs-versus-preservati-8d74bf281ef03d4bPharmaRadar360en2026-09-25T00:00:00.000ZDeproteinized calf blood extract With or without punctal plugs versus preservative-free sodium hyaluronate for glaucoma-associated ocular surface disease: a three-arm randomized controlled trialhttps://www.pharmaradar360.com/article/omentin-1-and-cardiovascular-disease-a-comprehensive-review-from-molecular-mecha-8982c91fdb3fc976PharmaRadar360en2026-09-25T00:00:00.000ZOmentin-1 and cardiovascular disease: a comprehensive review from molecular mechanisms to clinical translationhttps://www.pharmaradar360.com/article/clinical-characteristics-and-genotype-phenotype-correlation-analysis-in-279-pati-32e62f97fa08d151PharmaRadar360en2026-09-25T00:00:00.000ZClinical characteristics and genotype–phenotype correlation analysis in 279 patients with 5α-reductase type 2 deficiencyhttps://www.pharmaradar360.com/article/a-pre-market-open-label-single-arm-study-to-evaluate-b-bone-for-posterolateral-f-fd21f5760f204dbaPharmaRadar360en2026-09-25T00:00:00.000ZA pre-market, open-label, single-arm study to evaluate b.Bone for posterolateral fusion treatment of degenerative thoracolumbar, lumbar or lumbosacral spinal disease (b.Spine clinical trial)https://www.pharmaradar360.com/article/author-s-response-to-the-comments-on-long-term-clinical-and-functional-outcomes-344b23c04227b021PharmaRadar360en2026-09-25T00:00:00.000ZAuthor’s response to the Comments on: “Long-term clinical and functional outcomes of ultrasound-guided platelet-rich plasma injection for long head of the biceps tendinopathy: A prospective study”https://www.pharmaradar360.com/article/protein-drug-interaction-in-psoriasis-therapy-using-molecular-docking-and-molecu-8ace86625ddb7a15PharmaRadar360en2026-09-25T00:00:00.000ZPROTEIN-DRUG INTERACTION IN PSORIASIS THERAPY USING MOLECULAR DOCKING AND MOLECULAR DYNAMICS MODELINGhttps://www.pharmaradar360.com/article/effects-of-nurse-led-care-plan-and-parents-education-on-sleep-quality-and-behavi-c248428cdfe9a25aPharmaRadar360en2026-09-25T00:00:00.000ZEFFECTS OF NURSE-LED CARE PLAN AND PARENTS’ EDUCATION ON SLEEP QUALITY AND BEHAVIOR MODIFICATION IN PEDIATRIC PATIENTShttps://www.pharmaradar360.com/article/explainable-deep-learning-based-integration-of-multi-omics-data-rna-seq-dna-meth-4cf7874d8e5b91afPharmaRadar360en2026-09-25T00:00:00.000ZExplainable Deep Learning-Based Integration of Multi-Omics Data (RNA-Seq, DNA Methylation, and Mutation Profiles) for Predicting Chemotherapy Response and Identifying Key Biomarkers in Breast Cancer: A Reproducible Computational Framework and Demonstration Studyhttps://www.pharmaradar360.com/article/characterization-of-human-mesenchymal-stem-cell-according-to-delivery-route-and-966a5a72762014a4PharmaRadar360en2026-09-25T00:00:00.000ZCharacterization of human mesenchymal stem cell according to delivery route and its correlation with clinical-gynecological historyhttps://www.pharmaradar360.com/article/the-relationship-between-systemic-inflammation-response-index-and-clinical-and-h-cc45a3ab13df34bfPharmaRadar360en2026-09-25T00:00:00.000ZThe relationship between systemic inflammation response index and clinical and histopathological features in gastric cancerhttps://www.pharmaradar360.com/article/predicted-but-powerless-rethinking-clinical-predictors-against-patient-reported-77f69db8b6c5683dPharmaRadar360en2026-09-25T00:00:00.000ZPredicted but Powerless: Rethinking Clinical Predictors Against Patient-reported Recovery in Hospitalized Type 2 Diabeteshttps://www.pharmaradar360.com/article/quantifying-data-leakage-in-multimodal-clinical-augmentation-a-decomposition-fra-8482fc036ca2b068PharmaRadar360en2026-09-25T00:00:00.000ZQuantifying Data Leakage in Multimodal Clinical Augmentation: A Decomposition Framework and a Leakage-Free Evaluation Protocol for Parkinson's Disease Classificationhttps://www.pharmaradar360.com/article/demographic-and-clinical-profile-of-visits-to-the-pediatric-emergency-department-07b84b023040b184PharmaRadar360en2026-09-25T00:00:00.000ZDemographic and Clinical Profile of Visits to the Pediatric Emergency Department of a State Hospital: A 5-Year Retrospective Studyhttps://www.pharmaradar360.com/article/renal-denervation-for-hypertension-mechanisms-evidence-and-clinical-integration-89333ab93d31de1bPharmaRadar360en2026-09-25T00:00:00.000ZRenal Denervation for Hypertension ― Mechanisms, Evidence, and Clinical Integration ―https://www.pharmaradar360.com/article/an-lt-i-gt-in-vivo-lt-i-gt-factor-connecting-sustained-reactive-oxygen-species-c-19516830e05a44b5PharmaRadar360en2026-09-25T00:00:00.000ZAn &lt;i&gt;in Vivo&lt;/i&gt; Factor Connecting Sustained Reactive Oxygen Species Capture with Rapid Disposition: Quercetin Distribution into Hemoglobinhttps://www.pharmaradar360.com/article/exploring-the-impact-of-recipe-boxes-on-dietary-quality-and-food-agency-a-pilot-e1f30ebf291262adPharmaRadar360en2026-09-25T00:00:00.000ZExploring the impact of recipe boxes on dietary quality and food agency: a pilot and feasibility randomized controlled trial in households with school-aged childrenhttps://www.pharmaradar360.com/article/association-of-older-age-and-lower-body-mass-index-with-initial-teicoplanin-trou-8d0a8a8bd7f44a2ePharmaRadar360en2026-09-25T00:00:00.000ZAssociation of older age and lower body mass index with initial teicoplanin trough concentrations: a single-center retrospective cohort study